News
-
-
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Transfer of Listing to NEX and New Stock Option Plan
Intellipharmaceutics International Inc. announces listing transfer from TSX to NEX due to Cease Trade Order, new stock option plan approved. Company specializes in controlled-release drugs -
-
-
-
PRESS RELEASE
Intellipharmaceutics Announces Its Expected Delay in Filing Annual Audited Financial Statements and Annual Information Form
Intellipharmaceutics International Inc. announces delay in filing annual audited financial statements for the fiscal year ended November 30, 2023, due to applicable Canadian securities laws. Company working to expedite filing for compliance with OSC regulations -
PRESS RELEASE
Intellipharmaceutics International Inc. Announces Stock Option Grant
Intellipharmaceutics International Inc. issued 1,910,000 common share purchase options to certain eligible individuals under the stock option plan. The options vest over a period of 2 years and expire on February 5, 2034 -
PRESS RELEASE
Intellipharmaceutics International Inc. Receives Conditional Approval to List on the TSX Venture Exchange
Intellipharmaceutics International Inc., a pharmaceutical company, has received conditional approval to list its common shares on the TSX Venture Exchange as a Tier 2 Life Science Issuer. The company's management is working to meet the listing conditions, with expectations for a seamless transition from the Toronto Stock Exchange. Intellipharmaceutics specializes in the research, development, and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix ™ technology offers a multidimensional controlled-release drug delivery platform with various product candidates in the development pipeline. The company has also issued cautionary statements regarding forward-looking information. For further details, refer to the press release. -
-
PRESS RELEASE
Intellipharmaceutics Reports Director Election Results
-
Revolutionizing Fire Camps: NUE's Sustainable Power Solutions Shine at USDA Technology & Development Center
-
Save A Train Continues to Innovate with Rail Enrichment
-
Cameron Ashley Building Products Opens Third Location in the Badger State
-
Event Tickets Center is Named Official Secondary Ticketing Reseller Partner for Most Valuable Promotions and the Historic Jake Paul vs. Mike Tyson Fight
-
GRI Bio (NASDAQ: GRI) Participates in Virtual Investor CEO Connect
-
Amendment of the terms and conditions of the bond completed; Bondholders can convert bonds into shares
-
secunet Security Networks AG successfully holds Annual General Meeting – Broad approval for all proposed resolutions
-
TUI AG: Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
-
Fuller, Smith & Turner PLC: Transaction in own shares
-
AngloGold Ashanti US$9.0m (A$13.5m) Gold Farm-in Agreement
-
2024 Annual General Meeting: approval of all resolutions submitted to the Meeting
-
PR – ICADE – Success of the cash tender offer for a total amount of €350 million
-
AMOEBA: ORDINARY AND EXTRAORDINARY GENERAL MEETING OF 27 JUNE 2024 - Availability of preliminary documents
-
Availability of preparatory documents for the annual general meeting of June 13, 2024
-
Safran’s 2024 Annual General Meeting